EQUITY SECURITIES PORTFOLIO INVESTMENT (Tables)

3 Months Ended

Mar. 31, 2023

Investments, Debt and Equity Securities [Abstract]

Unrealized Gain (Loss) on Investments

Equity securities for the periods presented were comprised of the following:

Security Type	Cost		Gross Unrealized Gain		Gross Unrealized Loss		Fair Value
	(In thousands)
March 31, 2023:
Equity securities - Life Sciences Portfolio	$	28,498	$	15,337	$	(562)	$	43,273
Equity securities - other common stock	30,659		2,585		(15,793)		17,451
Total	$	59,157	$	17,922	$	(16,355)	$	60,724
December 31, 2022:
Equity securities - Life Sciences Portfolio	$	28,498	$	14,815	$	(617)	$	42,696
Equity securities - other common stock	34,885		4		(15,977)		18,912
Total	$	63,383	$	14,819	$	(16,594)	$	61,608

The following unrealized and realized gains or losses from our investment in the Life Sciences Portfolio are recorded in the change in fair value of equity securities and gain or loss on sale of equity securities, respectively, in the consolidated statements of operations:

	Three Months Ended March 31,
	2023		2022
	(In thousands)
Change in fair value of equity securities of public    companies	$	577	$	(171,640)
Gain on sale of equity securities of public    companies	—		59,488
Net realized and unrealized gain (loss)	$	577	$	(112,152)